100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
NUR 641E Final Exam 2023 | Advanced for the Nurse Educator with Complete Solutions $17.49   Add to cart

Exam (elaborations)

NUR 641E Final Exam 2023 | Advanced for the Nurse Educator with Complete Solutions

 1 view  0 purchase
  • Course
  • Institution

2. Medication safety organizations - ANSWER-The Institute for Safe MedicationPractices (ISMP) The Institute of Medicine (IOM) The Joint Commission The NationalCoordinating Council for Medication Error Reporting and Prevention (NCC MERP) Foodand Drug Administration (FDA) Safe Use InitiativeTwo basic...

[Show more]

Preview 3 out of 18  pages

  • September 6, 2023
  • 18
  • 2023/2024
  • Exam (elaborations)
  • Questions & answers
avatar-seller
NUR 641E final Exam Advanced for the
Nurse Educator with Complete Solutions
Pharmacokinetics involves - ANSWER-absorption, distribution, metabolism and
elimination).

Absorption: - ANSWER-absorption from the administration site either directly
or indirectly into the blood/plasma.

Distribution: - ANSWER-reversibly or irreversibly move from the bloodstream
into the interstitial and intracellular

Metabolism: - ANSWER-biotransformed via hepatic metabolism or by other
tissues.

Elimination: - ANSWER-tissues. lastly, the drug and its metabolites are
eliminated from the body.

route of administration with the highest bioavailability - ANSWER-intravenous;
putting entire dose into a patient's vein and bypassing absorption.

avoids first-pass metabolism - ANSWER-Intravenous route

administration has variable and erratic absorption. n - ANSWER-Rectal
administration

4. Steady state (SS) - ANSWER-absorption. n is usually reached within 4-5
half-lives of drug.

Half-life of a drug is - ANSWER-how long it takes for half the drug to be
excreted from the body. Determines how frequently the drug must be
administered. Predicts how long toxic effects can last.is constant with first-
order pharmacokinetics of a drug.

Zero-order (nonlinear) pharmacokinetics - ANSWER-means a drug is
metabolized at a constant rate per unit time.

CYP3A4 substrate drugs - ANSWER-may have enhanced activity if any
CYP3A4 inducer drugs are used along with it.

Drug development process involves these steps according to the FDA: -
ANSWER- Discovery: laboratory research to develop the new drug.
Preclinical research with animal testing for safety (Phase I). Clinical research
on human subjects for medication safety (Phase II). Clinical research in
humans comparing the new drug to accepted medications placebo
depending on the study (Phase III). FDA review of the results to determine
approval. Post marketing study to identify adverse effects not found in
earlier clinical studies (Phase IV)

,2. Medication safety organizations - ANSWER-The Institute for Safe
Medication Practices (ISMP) The Institute of Medicine (IOM) The Joint
Commission The National Coordinating Council for Medication Error
Reporting and Prevention (NCC MERP) Food and Drug Administration (FDA)
Safe Use Initiative

Two basic type of ADRS: - ANSWER-pharmacological and idiosyncratic.

85% to 90% of ADRS - ANSWER-are pharmacological.

Adverse drug reactions are usually preventable, - ANSWER-frequently occur
in a hospital or nursing home setting, and include medication errors, adverse
drug effects, and allergic idiosyncratic type reactions.

ADRS are not commonly reported; - ANSWER-the FDA does not mandate that
ADRS be reported.

Polypharmacy - ANSWER-involves using multiple health care providers for
care, using multiple medications, and using several pharmacies prescription
filling.

Angiotensin converting enzyme inhibitors (ACEIS): - ANSWER-lisinopril,
captopril, enalapril, ramipril, benazepril, fosinopril.

ACEIS reduce blood pressure enzyme. - ANSWER-by suppressing the
release of angiotensin-converting enzyme.

Important side effects of ACE inhibitors - ANSWER-Important include cough
and angioedema; discontinue the ACEI if angioedema occurs.

Angiotensin II receptor blocking agents (ARBS): - ANSWER-Icandesartan
(Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar),
telmisartan (Micardis) and valsartan (Diovan).

ARBS reduce blood pressure - ANSWER-by blocking angiotensin II receptors.

Essential (primary) hypertension - ANSWER-Essential (primary) accounts for
90% of cases; secondary hypertension may caused by chronic renal failure.

Nitroglycerin - ANSWER-Nitroglycerin is a nitrate drug that can be
administered IV, SL, a topical ointment and as a transdermal patch.

Nitrates are contraindicated - ANSWER-with PDE-5 inhibitors (e.g., sildenafil
and vardenafil)

Amiodarone is the antiarrhythmic - ANSWER-Of choice when there is
coexisting heart failure; can cause thyroid and pulmonary toxicity.

, Alpha-1 adrenergic stimulation - ANSWER-results in vasoconstriction and
increased blood pressure.

Alpha-1 adrenergic blockade - ANSWER-results in vasodilation and reduced
blood pressure.

Beta-1 adrenergic stimulation - ANSWER-by beta agonists (e.g.,
isoproterenol) results in increased heart rate, increased blood pressure, and
increased cardiac output.

Beta-1 adrenergic blockade results - ANSWER-in reduced heart rate, reduced
blood pressure, and reduced cardiac output.

Left heart failure - ANSWER-causes reduced delivery of oxygenated blood to
the body tissues.

Right heart failure - ANSWER-is associated with pulmonary disease and
increased pulmonary vascular resistance.

drug that relieves heart failure symptoms but does not reduce mortality -
ANSWER- furosemide.

Loop diuretics like furosemide - ANSWER-are potent diuretics, can cause
diuretic resistance and hypokalemia, and work on receptors in the thick
ascending renal loop of Henle.

Loop diuretics inhibit - ANSWER-reabsorption of sodium and chloride at this
site in the kidney.

Potassium-sparing diuretics: - ANSWER-spironolactone, triamterene.

Milrinone - ANSWER-phosphodiesterase inhibitor used for acute heart failure.

Children diagnosed with the tetralogy of Fallot can stop hypoxic spells -
ANSWER-by squatting down compensatory mechanism).

Patent ductus arteriosus (PDA) - ANSWER-is a congenital heart defect
with a continuous machine- like murmur heard over the left upper
sternal border in both systole and diastole, a bounding pulse and a
thrill on palpation.

PDA can be effectively treated - ANSWER-IV NSAIDS such as indomethacin.

Raynaud's disease - ANSWER-vasospastic disorder typically seen during cold
weather.

Raynaud's involves - ANSWER-the small arteries and arterioles in the fingers;
occasionally, the toes are also involved.

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller FLOYYD. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $17.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

81531 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$17.49
  • (0)
  Add to cart